title: Imatinib in the treatment of dermatofibrosarcoma protuberans.
abstract: Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with tendency to recur locally and only rarely metastasizes to vital organs. Surgery with wide margins remains the standard treatment. DFSP is characterized by specific chromosomal abnormalities involving the platelet derived growth factor B locus (PDGFB). In the majority of cases a supernumerary ring chromosome containing amplified t(17; 22) translocation or a linear unbalanced t(17; 22) containing the COL1A1 -PDGFB fusion gene is present. This molecular event causes aberrant expression of a functional PDGFB leading to activation of PDGFR. Imatinib mesylate is a tyrosine kinase inhibitor with activity against activated PDGFR, and has significant activity against DFSP. Clinical evidence suggests that it has a role in locally advanced and metastatic disease and clinical trials are ongoing examining its role in this rare but potentially fatal sarcoma.
authors.affiliation: 1st Medical Oncology Department, Hygeia Hospital, Marousi, Greece.
authors.forename: Stefanos V
authors.initials: SV
authors.lastname: Labropoulos
authors.forename: Evangelia D
authors.initials: ED
authors.lastname: Razis
references.citation: Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2072-6
references.pmid: 14606355
references.citation: Eur J Surg Oncol. 1992 Jun;18(3):241-8
references.pmid: 1607035
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3586-91
references.pmid: 12202658
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7669-75
references.pmid: 16234529
references.citation: J Clin Oncol. 2007 May 1;25(13):1760-4
references.pmid: 17470866
references.citation: Cancer Res. 1999 Aug 1;59(15):3719-23
references.pmid: 10446987
references.citation: J Clin Oncol. 2005 Feb 1;23(4):866-73
references.pmid: 15681532
references.citation: Genes Chromosomes Cancer. 1998 Oct;23(2):187-93
references.pmid: 9739023
references.citation: Curr Opin Oncol. 2006 Jul;18(4):341-6
references.pmid: 16721128
references.citation: CA Cancer J Clin. 1992 Mar-Apr;42(2):116-25
references.pmid: 1540852
references.citation: Cancer Genet Cytogenet. 1996 Jul 15;89(2):175-6
references.pmid: 8697429
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: N Engl J Med. 2006 Jun 15;354(24):2542-51
references.pmid: 16775235
references.citation: Genes Chromosomes Cancer. 2003 May;37(1):1-19
references.pmid: 12661001
references.citation: Cancer Res. 2001 Aug 1;61(15):5778-83
references.pmid: 11479215
references.citation: Curr Oncol Rep. 2006 Jul;8(4):291-6
references.pmid: 17254529
references.citation: Anticancer Drugs. 2005 Apr;16(4):461-6
references.pmid: 15746584
references.citation: Nature. 2002 Jul 4;418(6893):41-9
references.pmid: 12077603
references.citation: Semin Oncol. 2004 Apr;31(2 Suppl 6):30-6
references.pmid: 15176002
references.citation: J Clin Oncol. 1996 Aug;14(8):2365-9
references.pmid: 8708729
references.citation: Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):823-7
references.pmid: 9531366
references.citation: Cancer Genet Cytogenet. 1990 Oct 15;49(2):199-202
references.pmid: 2208055
references.citation: Br J Dermatol. 2004 Jul;151(1):235-7
references.pmid: 15270901
references.citation: Int J Cancer. 2001 May 1;92(3):354-60
references.pmid: 11291071
references.citation: Int J Cancer. 2002 Aug 20;100(6):623-6
references.pmid: 12209598
references.citation: Cancer. 2000 Jun 15;88(12):2711-20
references.pmid: 10870053
references.citation: Anticancer Drugs. 2006 Nov;17(10):1223-5
references.pmid: 17075323
references.citation: Pediatr Blood Cancer. 2005 May;44(5):511-5
references.pmid: 15503291